Flagship Ventures, a Cambridge, MA-based venture capital firm focused on therapeutics, health technologies, and sustainability, is raising a $350m opportunity fund.
According to a regulatory form filed with the SEC, the name of the new vehicle is Flagship Ventures Opportunities Fund I, L.P..
Founded in 2000, the firm has conceived and launched more than 40 companies through its innovation foundry, called VentureLabs™, and supported and developed another 45 companies working with collaborators and academic innovations.
The firm manages over $1.4 billion in capital across five funds.
The portfolio includes Acceleron (NASDAQ: XLRN), Agios (NASDAQ: AGIO), Seres Therapeutics (NASDAQ: MCRB), T2 Biosystems (NASDAQ: TTOO), as well as private companies Editas Medicine, Moderna Therapeutics and Syros Pharmaceuticals.